EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Guided PEGylation of IL‑1Ra Preserves Fold and Antagonist Function

Işılay Göktan, Çaǧdaş Daǧ iD, Ahmet Gül, Seda Kizilel iD

Molecular Pharmaceutics · 05.10.2026 · 23 (10) · 4820-4831

DOI: 10.1021/acs.molpharmaceut.6c00060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 23.06.2026. Verfasst von Işılay Göktan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemical and Biological Engineering, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul34450, Turkey. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Polyethylene Glycols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific and Technological Research Council of Turkey (TÜBITAK).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rational design of PEGylated protein therapeutics requires mechanistic understanding of how coupling chemistry and PEG size jointly determine product homogeneity, receptor engagement, and structural integritythe properties that collectively govern whether a conjugate is a viable candidate for further development. Anakinra (recombinant interleukin-1 receptor antagonist, IL-1Ra) is an approved anti-inflammatory biologic whose short systemic residence necessitates daily subcutaneous injection and is associated with steep peak−trough exposure fluctuations that, in chronic high-dose regimens, have been linked to IL-1Ra-derived systemic amyloidosis. PEGylation offers a chemically established route to increase the apparent molecular size of IL-1Ra and thereby reduce renal filtration and smooth exposure, but the structural and functional consequences of conjugation have never been characterized at residue resolution for this targeta gap that limits informed design choices between available chemistries. Here, we address this gap by establishing a head-to-head characterization framework comparing site-specific thiol-maleimide conjugation and random amino-coupling on a uniformly 15N-labeled recombinant IL-1Ra variant (M143V) that preserves all native conjugation sites and is potency-matched to Anakinra. Across a 5−20 kDa PEG ladder at a substoichiometric 0.5:1 PEG:protein feed, site-specific thiol-maleimide coupling yielded substantially higher conversion (∼81%) and a homogeneous single-species di-PEGylated (DoP 2) conjugate, whereas random amino-coupling produced heterogeneous mixtures across all PEG sizes (∼33−36% conversion, multiple degrees of polymerization). Purified single-species conjugates were benchmarked under a fixed IL-1β EC80 challenge in HEK-Blue reporter cells; all retained full maximal efficacy but exhibited chemistry- and size-dependent right-shifts in IC50, indicating steric modulation of receptor engagement rather than loss of function. To directly establish whether PEG attachment perturbs structural integrity, 2D 1H−15N HSQC NMR on the 15N-labeled thiol-PEG10 conjugate demonstrated a preserved global fold with localized chemical-shift perturbations near cysteine-proximal surface regions, confirming site-selective modification and intact binding scaffold. Together, these data establish the conjugation quality, antagonist activity, and structural integrity of the lead conjugate as the prerequisite characterization foundation for its further development and provide a transferable analytical framework for the rational design of PEGylated cytokine therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin 1 Receptor Antagonist ProteinPolyethylene GlycolsHumansMaleimidesRecombinant ProteinsProtein Folding

Stichwörter der Autor:innen

PEGylationProtein therapeuticsamino-couplingthiol-maleimide conjugation

Substanzen

Interleukin 1 Receptor Antagonist ProteinPolyethylene GlycolsMaleimidesRecombinant Proteinsmaleimide

Autor:innen und Institutionen

  • Chemical and Biological Engineering, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul34450, Turkey.
  • Nanofabrication and Nanocharacterization Center for Scientific and Technological Advanced Research (N2STAR), Koç University, Rumelifeneri Yolu, Sariyer, Istanbul34450, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Istanbul University Medical School, Turgut Özal Millet Cd, Fatih, Istanbul34093, Turkey.

ORCID-Profile: Çaǧdaş Daǧ, Seda Kizilel

Förderung

  • The Scientific and Technological Research Council of Turkey (TÜBITAK)

Zitieren

APA

Göktan, I., Daǧ, Ç., Gül, A., & Kizilel, S. (2026). Structure-Guided PEGylation of IL‑1Ra Preserves Fold and Antagonist Function. Molecular Pharmaceutics, 23(10), 4820-4831. https://doi.org/10.1021/acs.molpharmaceut.6c00060

Vancouver

Göktan I, Daǧ Ç, Gül A, Kizilel S. Structure-Guided PEGylation of IL‑1Ra Preserves Fold and Antagonist Function. Molecular Pharmaceutics. 2026;23(10):4820-4831. doi:10.1021/acs.molpharmaceut.6c00060

BibTeX
@article{Gktan2026,
  author = {Göktan, Işılay and Daǧ, Çaǧdaş and Gül, Ahmet and Kizilel, Seda},
  title = {Structure-Guided PEGylation of IL‑1Ra Preserves Fold and Antagonist Function},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {10},
  pages = {4820--4831},
  doi = {10.1021/acs.molpharmaceut.6c00060}
}
Kostenlos starten →